Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) initiated a human factors/usability study for NASARIX™, its intranasal allergy blocker, executed to align with FDA human factors and usability engineering guidance. The program aims to confirm labeling, instructions for use, and user interaction, to de-risk downstream regulatory review and support a streamlined path toward clinical development.

Successful completion could provide regulatory evidence of readiness for clinical evaluation and supports the company’s plan to start clinical trials in Q3 2026. The company is currently a pre-clinical-stage biotechnology developer of intranasal protective solutions.

Positive

• Usability study aligned with FDA human factors guidance
• Study intended to de-risk downstream regulatory review
• Clinical trials planned to begin in Q3 2026

Negative

• Company is currently at the pre-clinical stage
• No clinical trials have started yet

News Market Reaction – PLRZ

-2.00%

1 alert

-2.00% News Effect

+7.5% Peak Tracked

-$533K Valuation Impact

$26M Market Cap

0.2x Rel. Volume

On the day this news was published, PLRZ declined 2.00%, reflecting a moderate negative market reaction. Argus tracked a peak move of +7.5% during that session. This price movement removed approximately $533K from the company's valuation, bringing the market cap to $26M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Planned trial start: Q3 2026 Shelf capacity: $50,000,000

2 metrics

Planned trial start Q3 2026 Expected commencement of NASARIX™ clinical trials

Shelf capacity $50,000,000 Form F-3 shelf registration for future securities offerings

Market Reality Check

Price: $14.41 Vol: Volume 150,962 is slightl...

normal vol

$14.41 Last Close

Volume Volume 150,962 is slightly below the 20-day average of 161,555, suggesting no major volume spike with the news. normal

Technical Shares at $15.99 are trading below the 200-day MA of $92.24 and far under the $2,550 52-week high, despite being well above the $2.88 low.

Peers on Argus

PLRZ gained 9.6% while peers showed mixed moves: SXTP was up 178.4999966621399% ...

1 Up 1 Down

PLRZ gained 9.6% while peers showed mixed moves: SXTP was up 178.4999966621399% and ADTX was down 4.14000004529953%, indicating a stock-specific reaction rather than a broad biotech move.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Strategic investments	Positive	+0.7%	Board authorized exploring revenue-generating investments using strong cash position.
Jan 08	Branding milestone	Positive	+8.4%	Completed branding of PL-14 as NASARIX™ supporting future commercialization.
Jan 05	Pre-clinical data	Positive	-0.8%	Reported significant allergen-blocking pre-clinical results for PL-14 versus comparator.
Jan 02	Product positioning	Positive	+50.2%	Highlighted PL-16 viral blocker amid severe flu season and FDA pre-request filing.
Dec 29	Real asset plans	Positive	-1.4%	Board approved exploring revenue-generating real assets while advancing pipeline.

Pattern Detected

Recent news has generally been positive, with three of the last five announcements seeing share price gains within 24 hours, though there are instances where favorable updates coincided with mild declines.

Recent Company History

Over the past month, Polyrizon has reported several milestones across branding, pre-clinical data, and strategic investment plans. On Dec 29, 2025 and Jan 13, 2026, the company highlighted using a strong cash position and debt-free balance sheet to explore revenue-generating opportunities while keeping focus on its intranasal pipeline. Early January brought branding of PL-14 as NASARIX™ and pre-clinical efficacy data, alongside PL-16 positioning during a severe flu season. Today’s usability study launch fits into this sequence as another step toward clinical readiness.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$50,000,000 registered capacity

An effective Form F-3 shelf filed on Nov 07, 2025 allows Polyrizon to offer up to $50,000,000 of securities, including shares, warrants and units, via various methods such as at-the-market offerings and block trades. The shelf has seen 0 takedowns so far and remains available through Nov 07, 2028, providing flexibility for future capital raises that could be used for corporate and development activities.

Market Pulse Summary

This announcement advances NASARIX™ by launching an FDA-guided human factors and usability program, ...

Analysis

This announcement advances NASARIX™ by launching an FDA-guided human factors and usability program, intended to support a smoother regulatory review and readiness for clinical trials targeted for Q3 2026. It follows recent branding, pre-clinical data, and strategic investment updates that have shaped Polyrizon’s trajectory. Investors may monitor completion of this study, subsequent clinical trial initiation, and any use of the existing $50,000,000 shelf registration as key markers of both development progress and funding strategy.

Key Terms

human factors, usability engineering, intranasal, U.S. Food and Drug Administration (FDA)

4 terms

human factors technical

"Executed in accordance with FDA human factors and usability engineering guidance"

Human factors are the study and design of how people interact with products, processes, and work environments to make tasks safer, easier, and less error-prone. For investors, good human factors practices reduce the risk of accidents, product failures, regulatory penalties and costly rework, and can boost productivity and customer satisfaction — much like a well-designed car dashboard that helps drivers operate controls without distraction.

usability engineering technical

"Executed in accordance with FDA human factors and usability engineering guidance"

Usability engineering is the practice of designing and testing products, interfaces, or systems to make them easy, efficient, and safe for real people to use. For investors, it matters because better usability speeds customer adoption, lowers support and error-related costs, and can be decisive for regulatory approval or market acceptance—similar to ensuring a front door is easy to find and open so visitors enter without trouble.

intranasal medical

"a pre-clinical-stage biotechnology company developing intranasal protective solutions"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

U.S. Food and Drug Administration (FDA) regulatory

"alignment with U.S. Food and Drug Administration (FDA) requirements for critical product elements"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

AI-generated analysis. Not financial advice.

Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development

Raanana, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the initiation of a key usability (Human Factors) study program for its lead product candidate, NASARIX™, an innovative intranasal allergy blocker designed for broad consumer use.

The study marks an important value-inflection milestone in Polyrizon’s development roadmap and is being conducted to confirm alignment with U.S. Food and Drug Administration (FDA) requirements for critical product elements, including labeling, instructions for use, and overall user interaction. Executed in accordance with FDA human factors and usability engineering guidance, the study is intended to de-risk downstream regulatory review and support a streamlined path toward clinical development.

Successful completion of the usability program will potentially provide essential regulatory evidence supporting NASARIX™ readiness for clinical evaluation. This milestone represents an important step toward the planned initiation of Polyrizon’s clinical trials, which are expected to commence in Q3 2026, positioning the company for continued advancement along its regulatory and potential commercialization strategy.

“This usability study is a key milestone in advancing NASARIX™ toward clinical trials, which are expected to commence in Q3 2026,” said Tomer Izraeli, CEO of Polyrizon. “It underscores our commitment to FDA-aligned development, patient safety, and user-centered intranasal solutions.”

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its development roadmap, the planned initiation of Polyrizon’s clinical trials, which are expected to commence in Q3 2026, continued advancement along its regulatory and potential commercialization strategy and its commitment to FDA-aligned development, patient safety, and user-centered intranasal solutions. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty

Investor Relations

IR@polyrizon-biotech.com

FAQ

What is Polyrizon announcing about NASARIX™ usability studies (PLRZ)?

Polyrizon initiated a human factors/usability study for NASARIX™ to confirm labeling, instructions, and user interaction aligned with FDA guidance.

How does the NASARIX™ usability program affect PLRZ's regulatory path?

The study is intended to de-risk downstream regulatory review and provide evidence to support clinical evaluation readiness.

When does Polyrizon expect to start NASARIX™ clinical trials (PLRZ)?

Polyrizon plans to commence clinical trials in Q3 2026.

What stage is Polyrizon currently at with NASARIX™ (PLRZ)?

Polyrizon is a pre-clinical-stage biotechnology company developing NASARIX™.

What elements will the NASARIX™ usability study evaluate for PLRZ?

The study will assess critical product elements including labeling, instructions for use, and overall user interaction.